Post-infectious IBS
Post-infectious IBS (PI-IBS) is irritable bowel syndrome that begins after an acute bout of infectious gastroenteritis, bacterial, viral, or protozoal, in a person who did not previously meet IBS criteria. Prospective cohorts suggest roughly 7–15% of those with documented gastroenteritis develop IBS symptoms at 3–12 months (Marshall et al., 2019), with risk higher after severe or prolonged acute illness, female sex, and psychological stressors in some studies. Mechanisms proposed include persistent motility dysfunction, visceral hypersensitivity, immune activation, and microbiome shifts, none of which a single consumer stool kit diagnoses.
PI-IBS is a clinical syndrome (Rome IV), not a taxon profile. Sequencing may show reduced diversity early after infection in some longitudinal work, overlapping acute diarrhoea patterns in meta-analyses (Duvallet et al., 2017), expected transient disruption is easy to mislabel chronic PI-IBS.
For report routing: Reading your microbiome report.
What not to conclude
| Situation | Weak conclusion | More accurate framing |
|---|---|---|
| Dysbiosis 4 weeks after infection | Permanent PI-IBS | Acute post-infectious microbiome disruption often partially recovers |
| Low diversity on kit | Autoimmune gut disease | Non-specific; calprotectin and history drive workup |
| Normal report 6 months later | Never had PI-IBS | Symptoms can persist with normalised composition |
| Positive breath test | PI-IBS equals SIBO | Overlap exists; pathways differ, Methane and colonic gas |
| High Enterobacteriaceae | Need antibiotics | Post-infectious blooms may resolve without treatment |
| Probiotic marketing post-Campylobacter | Proven PI-IBS prevention | Strain-specific; prevention trials mixed |
Definition and epidemiology
Rome IV classifies IBS by current symptoms; PI-IBS is a clinical descriptor for onset after infection, not a separate Rome code on every chart.
| Factor | Association with PI-IBS risk (prospective studies) |
|---|---|
| Severity of acute illness | Longer duration, bloody stools, weight loss during acute phase |
| Sex | Higher risk in women in several cohorts |
| Psychological distress | Anxiety/depression during acute illness predicts persistence |
| Pathogen type | Bacterial (e.g. Campylobacter, Shigella, Salmonella) most studied |
| Age | Middle years over-represented in some series |
Many people with post-infectious symptoms recover by 12–24 months without specific microbiome intervention (Spiller & Garsed, 2009).
Mechanisms, motility, barrier, immune
PI-IBS is multifactorial; microbiome change is one thread.
Motility: Persistently altered transit and heightened colonic contractility after inflammation (Spiller, 2007).
Barrier: Increased permeability in subsets after gastroenteritis, overlaps intestinal barrier literature; stool does not measure permeability directly (Zonulin contested).
Immune: Low-grade mucosal immune activation may persist after pathogen clearance, distinct from IBD but can elevate calprotectin transiently.
Microbiome: Reduced diversity and altered dominant taxa in some 3–6 month follow-up studies; direction of causality unclear (cause vs consequence of symptoms).
How PI-IBS differs from idiopathic IBS for management
| Aspect | PI-IBS | Idiopathic IBS |
|---|---|---|
| Onset story | Clear infectious gastroenteritis | Gradual or unclear |
| Natural history | Higher spontaneous improvement rate in some cohorts | More chronic course on average |
| Bile acid diarrhea | Check if persistent watery diarrhea | Same differential |
| SIBO/IMO testing | Consider if bloating and carbohydrate triggers dominate | Same |
| Diet first line | Low-FODMAP, fiber titration per subtype, IBS subtypes | Same toolbox |
| Microbiome kit timing | Wait ≥4 weeks after acute phase for “stable” snapshot | Less timing constraint |
PI-IBS does not exempt patients from red-flag evaluation, new bleeding or weight loss still triggers organic workup including IBD exclusion.
Testing and follow-up
| Test | Role in PI-IBS context |
|---|---|
| Stool culture/PCR during acute illness | Identifies pathogen, baseline for PI-IBS story |
| Calprotectin | Rules out ongoing inflammatory pathology if elevated |
| Celiac serology | If diarrhea persists |
| Breath testing | Malabsorption / IMO/SIBO hypotheses, not PI-IBS-specific |
| Consumer microbiome panel | Optional context; no validated PI-IBS classifier |
| Colonoscopy | If alarm features or persistent unexplained diarrhea |
Retesting microbiome composition: see Retesting over time, compare only with infection date documented.